Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases

Rhea-AI Summary

Gilead Sciences has signed the Kigali Declaration to combat neglected tropical diseases (NTDs) by 2030, reinforcing its commitment to global health. This declaration, launched during the Commonwealth Heads of Government Meeting, aims to eliminate 20 diseases by 2030. Gilead's CEO, Daniel O'Day, emphasized the company's long history of supporting NTD efforts. Gilead will continue its product donations for visceral leishmaniasis until 2027, invest in health equity initiatives, and lead discussions on environmental factors contributing to NTDs.

Positive

• Reaffirmed commitment to global health equity through the Kigali Declaration.
• Continued product donations to the WHO's visceral leishmaniasis elimination program until 2027.
• Investment in innovative global initiatives targeting health equity.

Negative

• None.

- By signing the Kigali Declaration, Gilead joins the global community committed to ending neglected tropical diseases by 2030 -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political declaration is an important milestone for the World Health Organization’s 2030 road map which includes global targets to prevent, control and in some cases eliminate 20 diseases and disease groups by 2030.

“Gilead has a long history of supporting the control and elimination of neglected tropical diseases. In signing the Kigali Declaration, we are reaffirming our commitment as part of our ongoing efforts to advance global health equity,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The progress made against NTDs to date demonstrates the power of collaboration and unrelenting focus.”

As Gilead marks 30 years of partnership with the World Health Organization (WHO) to end visceral leishmaniasis (VL), the company also commits to driving private sector engagement towards the Sustainable Development Goals for health and global partnership to achieve not only the control of NTDs but the elimination of their root causes, as well. In particular, Gilead will:

• Continue its product donation to the VL elimination program led by WHO between 2023- and 2027.
• Support and invest in innovative global initiatives that will address health equity.
• Spearhead and contribute to a broad stakeholder dialogue driving pharmaceutical sector engagement and investment in tackling environmental issues causing NTDs, such as climate change and lack of access to clean water.

Find more information about the 2030 Neglected Tropical Disease road map here: https://www.who.int/teams/control-of-neglected-tropical-diseases/ending-ntds-together-towards-2030

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220624005468/en/

Jacquie Ross, Investors

(408) 656-8793



Bahar Turkoglu, Media

+44 7768 555517

Source: Gilead Sciences, Inc.

FAQ

What is the Kigali Declaration signed by Gilead (GILD)?

The Kigali Declaration is a commitment by Gilead to help eliminate neglected tropical diseases (NTDs) by 2030, succeeding the London Declaration.

How long will Gilead continue product donations for visceral leishmaniasis?

Gilead will continue product donations to the WHO's visceral leishmaniasis elimination program from 2023 to 2027.

What are Gilead's commitments under the Kigali Declaration?

Gilead commits to product donations, investing in health equity initiatives, and addressing environmental factors causing NTDs.

Why is the Kigali Declaration important for Gilead shareholders?

The Kigali Declaration underscores Gilead's ongoing commitment to global health, potentially enhancing the company's reputation and investor confidence.

When was the Kigali Declaration launched?

The Kigali Declaration was launched on the margins of the Commonwealth Heads of Government Meeting.